Currently, there are 63.81M common shares owned by the public and among those 37.01M shares have been available to trade.
The company’s stock has a 5-day price change of -12.73% and -40.54% over the past three months. LRMR shares are trading -17.14% year to date (YTD), with the 12-month market performance down to -11.92% lower. It has a 12-month low price of $3.01 and touched a high of $13.68 over the same period. LRMR has an average intraday trading volume of 860.86K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -31.97%, -44.31%, and -49.96% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Larimar Therapeutics Inc (NASDAQ: LRMR) shares accounts for 60.93% of the company’s 63.81M shares outstanding.
It has a market capitalization of $240.55M and a beta (3y monthly) value of 0.88. The earnings-per-share (ttm) stands at -$1.15. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.98% over the week and 11.00% over the month.
Earnings per share for the fiscal year are expected to decrease by -44.76%, and -35.41% over the next financial year.
Looking at the support for the LRMR, a number of firms have released research notes about the stock. Oppenheimer stated their Outperform rating for the stock in a research note on October 16, 2024, with the firm’s price target at $26. Wedbush coverage for the Larimar Therapeutics Inc (LRMR) stock in a research note released on October 03, 2024 offered a Outperform rating with a price target of $22. H.C. Wainwright was of a view on October 02, 2024 that the stock is Buy, while Robert W. Baird gave the stock Outperform rating on September 04, 2024, issuing a price target of $16. Leerink Partners on their part issued Outperform rating on April 03, 2024.
